<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01352975</url>
  </required_header>
  <id_info>
    <org_study_id>110147</org_study_id>
    <secondary_id>11-EI-0147</secondary_id>
    <nct_id>NCT01352975</nct_id>
  </id_info>
  <brief_title>Study of Dark Adaptation in Age-Related Macular Degeneration</brief_title>
  <official_title>Longitudinal Investigation of Dark Adaptation in Participants With Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:

        -  Age-related macular degeneration (AMD) is a leading cause of vision loss in individuals
           over 55 years of age. It can cause permanent loss of central vision, which is important
           for seeing fine details and long distances. AMD has two forms: wet AMD and dry AMD. Most
           people with AMD have dry AMD. But dry AMD can progress to wet AMD. Wet AMD is the more
           serious form and can result in severe vision loss.

        -  A method to identify and monitor the early to middle stages of AMD may help researchers
           develop new treatments to stop the disease before it becomes severe. In early dry AMD,
           people cannot see well at night. Researchers want to study whether a procedure that
           measures how the eye adjusts to the dark can help to identify and monitor early to
           middle dry AMD.

      Objectives:

      - To evaluate the effectiveness of using a dark adaptation protocol to identify and monitor
      early to middle dry age-related macular degeneration.

      Eligibility:

      - People at least 50 years of age who have no AMD. Others who have early to middle dry AMD in
      at least one eye.

      Design:

        -  People will be screened with a physical examination, medical history, blood and urine
           tests, and a full eye exam.

        -  This study will last 5 years and require at least 9 visits to NIH. (First visit; study
           visits at months 3, 6, 12, 18, and 24; and 3 yearly followup visits).

        -  Up to 10 people will be asked to come back to the clinic 1 week after their first visit.
           They will be asked to test the device to be used in the study.

        -  Participants will have baseline exams. These questions will be about problems that
           affect their eyes under different lighting conditions.

        -  At every visit, participants will answer questions about general health and current
           medications (including any vitamins or supplements). They will also have a full eye exam
           and a 20- to 40-minute test. This test measures how fast the eyes recover in response to
           decreasing levels of light. The test also measures how sensitive the eyes are to these
           conditions.

        -  Participants will continue to have these tests at the yearly followup examinations. They
           will be treated with the standard of care for any eye conditions they have or may
           develop during the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: This study is designed to investigate the use of dark adaptation as a functional
      endpoint for progression of eyes with no to intermediate age-related macular degeneration
      (AMD).

      Study Population: Two hundred forty (240) participants will be initially accrued; however, up
      to 280 participants who meet the eligibility criteria may be enrolled. Participants will have
      varying degrees of severity of AMD (Groups 0, 1, 2, 3 and 4). Group 0 (N=40) is defined as
      participants without AMD meaning no large drusen (greater than or equal to 125 microns) or
      advanced AMD in either eye. Group 1 (N=40) is defined as participants with large drusen
      (greater than or equal to 125 microns) in the study eye and no large drusen or advanced AMD
      (choroidal neovascularization (CNV) or geographic atrophy (GA)) in the fellow eye. Group 2
      (N=40) is defined as participants with bilateral large drusen (greater than or equal to 125
      microns) with or without retinal pigment epithelial hypo/hyperpigmentary changes. Group 3
      (N=40) is defined as participants with large drusen (greater than or equal to 125 microns) in
      the study eye and advanced AMD (CNV or GA) in the fellow eye. Group 4 (N=40) is defined as
      participants with findings of reticular pseudodrusen (RPD) defined as having (1) the presence
      of reticular interlacing patterns on at least one en face imaging method (color photography,
      autofluorescence or infrared) and (2) confirmation of previously described findings of
      hyperreflective material located between the retinal pigment epithelium (RPE) and the
      photoreceptor ellipsoid zone on SD OCT in those areas. Current participants in this study
      have been graded and categorized into this cohort. Up to 40 diabetic participants will be
      recruited.

      Design: This is a single center, exploratory, observational, longitudinal evaluation of dark
      adaptation response in AMD participants over five years and long-term evaluation of dark
      adaptometry (DA) change as a predictor for AMD progression and visual acuity (VA) loss.

      Outcome Measures: The primary outcome is to determine mean change, including the distribution
      of change, in dark adaptation response between baseline and months 12 and 24 for Groups 0, 1,
      2, 3 and 4. Reproducibility between the Adapt RxTM (the research prototype of the AdaptDxTM)
      and the commercial AdaptDxTM will be evaluated in a minimum of 10 participants with repeat
      testing performed one week (- 6 days/+ 14 days) following the baseline visit. The secondary
      outcomes for each of the five groups are to determine mean change in dark adaptation response
      from baseline at months 3, 6, 18, 36, 48 and 60 and to determine mean best-corrected visual
      acuity (BCVA) of the study eye from baseline at months 3, 6, 12, 18, 24, 36, 48 and 60.
      Exploratory outcomes for each of the five groups are to correlate mean BCVA of the study eye
      with mean dark adaptation response at baseline and months 3, 6, 12, 18, 24, 36, 48 and 60 and
      to correlate AMD severity with dark adaptation response at baseline and months 3, 6, 12, 18,
      24, 36, 48 and 60. This study will also analyze renal function in AMD participants.
      Additionally, exploratory analysis of the small sample of diabetic participants will also be
      performed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 11, 2011</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is to determine mean change, including the distribution of change, in dark adaptation response between baseline and months 12 and 24 for Groups 0-3.</measure>
    <time_frame>Baseline, 12 months, 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine mean change in dark adaptation response from baseline at months 3, 6, 18, 36, 48 and 60.</measure>
    <time_frame>Baseline, months 3,6,12,18,24,36,48 and 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The exploratory outcomes are to correlate mean BCVA with mean dark adaptation response and AMD severity with dark adaptation response at baseline compared with all time points. Exploratory analysis of the diabetic participants will be performed.</measure>
    <time_frame>Baseline, months 3,6,12,18,24,36,48 and 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine mean BCVA from baseline at months 3, 6, 12, 18, 24, 36, 48 and 60.</measure>
    <time_frame>Baseline, months 3,6,12,18,24,36,48 and 60</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Participants will be eligible if the following inclusion criteria are met:

        Participant is able to understand and sign the protocol s informed consent document.

        Participant is able to complete and comply with study assessments for the full duration of
        the study.

        Participant is greater than or equal to 50 years of age.

        Participant has a BCVA score of greater than or equal to 20/100 (Snellen equivalent) in
        study eye.

        Participant qualifies for one of the following groups based on AMD grading as defined
        below. Advanced AMD is defined in Appendix 1.

        Group 0: Participant without AMD defined as no large drusen or advanced AMD in either eye;

        Group 1: Participant has at least one large drusen (greater than or equal to 125 microns)
        in the study eye and no large drusen or advanced AMD in the fellow eye;

        Group 2: Participant has bilateral large drusen (greater than or equal to 125 microns) with
        or without retinal pigment epithelial hypo/hyperpigmentary changes;

        Group 3: Participant has at least one large drusen (greater than or equal to 125 microns)
        in the study eye and advanced AMD in the fellow eye.

        Group 4: Participant has reticular pseudodrusen in the study eye defined as having (1) the
        presence of RPD on at least one en face imaging method (color photography, autofluorescence
        or infrared) and (2) confirmation of previously described findings of hyperreflective
        material located between the retinal pigment epithelium (RPE) and the photoreceptor
        ellipsoid zone on SD OCT in those areas.

        EXCLUSION CRITERIA:

        Participants who meet any of the following criteria will be excluded from this study:

        Participant has advanced AMD in the study eye at the baseline visit.

        Participant has other active ocular or macular diseases (e.g., diabetic macular edema,
        retinal vein occlusion, Stargardt s disease or cone-rod dystrophy) or other known ocular
        disorders that have caused a visual field deficit (e.g., glaucoma with known visual field
        defect) in the study eye.

        Participant has a fixation deficit in the study eye that would prevent the participant from
        performing the AdaptRxTM/AdaptDxTM dark adaptation protocol.

        Participant has a medical condition that the investigator feels would prevent the
        participant from complying with or being able to complete the study assessments

        Participant had cataract surgery in the study eye within three months prior to enrollment.

        Participant has an oral intake of high doses of vitamin A palmitate supplement (greater
        than or equal to 10,000 international units (IU) per day).

        Participant has or had hepatitis or liver disease. Abnormally low vitamin A can alter dark
        adaptation and chronic liver disease has been associated with low vitamin A.

        Participant has a history of vitamin A deficiency.

        Participant is an NEI employee or subordinate or co-worker of an investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine A Cukras, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Eye Institute (NEI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angel H Garced, R.N.</last_name>
    <phone>(301) 594-3141</phone>
    <email>garceda@nei.nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine A Cukras, M.D.</last_name>
    <phone>(301) 435-5061</phone>
    <email>cukrasc@mail.nih.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@cc.nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2011-EI-0147.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984 Nov;102(11):1640-2.</citation>
    <PMID>6208888</PMID>
  </reference>
  <reference>
    <citation>Friedman DS, O'Colmain BJ, Mu√±oz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J; Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004 Apr;122(4):564-72. Erratum in: Arch Ophthalmol. 2011 Sep;129(9):1188.</citation>
    <PMID>15078675</PMID>
  </reference>
  <reference>
    <citation>Scilley K, Jackson GR, Cideciyan AV, Maguire MG, Jacobson SG, Owsley C. Early age-related maculopathy and self-reported visual difficulty in daily life. Ophthalmology. 2002 Jul;109(7):1235-42.</citation>
    <PMID>12093644</PMID>
  </reference>
  <reference>
    <citation>Grune T, Lietz G, Palou A, Ross AC, Stahl W, Tang G, Thurnham D, Yin SA, Biesalski HK. Beta-carotene is an important vitamin A source for humans. J Nutr. 2010 Dec;140(12):2268S-2285S. doi: 10.3945/jn.109.119024. Epub 2010 Oct 27.</citation>
    <PMID>20980645</PMID>
  </reference>
  <verification_date>February 9, 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2011</study_first_submitted>
  <study_first_submitted_qc>May 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2011</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Age Related Macular Degeneration (AMD)</keyword>
  <keyword>Dark Adaptation</keyword>
  <keyword>Age Related Macular Degeneration</keyword>
  <keyword>AMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

